Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 11;40(4):335-337.
doi: 10.1016/j.ccell.2022.02.005. Epub 2022 Feb 16.

Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

Lorenzo Canti  1 , Kevin K Ariën  2 , Isabelle Desombere  3 , Stéphanie Humblet-Baron  4 , Pieter Pannus  3 , Leo Heyndrickx  5 , Aurélie Henry  6 , Sophie Servais  7 , Evelyne Willems  6 , Grégory Ehx  1 , Stanislas Goriely  8 , Laurence Seidel  9 , Johan Michiels  5 , Betty Willems  5 , Maria E Goossens  3 , Yves Beguin  7 , Arnaud Marchant  8 , Frédéric Baron  10
Affiliations

Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

Lorenzo Canti et al. Cancer Cell. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of interests F.B. has received travel grants from Pfizer, Celgene, Abbvie, Novartis, and Sanofi as well as honoraria from Merck and Abbvie. The other authors declare no relevant conflict of interest.

References

    1. Ariën K.K., Heyndrickx L., Michiels J., Vereecken K., Van Lent K., Coppens S., Pannus P., Martens G.A., Van Esbroeck M., Goossens M.E., et al. Three doses of the BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern. Preprint at MedRxiv. 2021 2021.12.23.21268316. - PMC - PubMed
    1. Canti L., Humblet-Baron S., Desombere I., Neumann J., Pannus P., Heyndrickx L., Henry A., Servais S., Willems E., Ehx G., et al. Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. J. Hematol. Oncol. 2021;14:174. - PMC - PubMed
    1. Gruell H., Vanshylla K., Tober-Lau P., Hillus D., Schommers P., Lehmann C., Kurth F., Sander L.E., Klein F. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat. Med. 2022 doi: 10.1038/s41591-021-01676-0. - DOI - PMC - PubMed
    1. Jurdi A.A., Gassen R.B., Borges T.J., Lape I.T., Morena L., Efe O., Solhjou Z., Fekih R.E., Deban C., Bohan B., et al. Diminished antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients. MedRxiv. 2022 Preprint at 2022.01.03.22268649. - PMC - PubMed
    1. Le Bourgeois A., Coste-Burel M., Guillaume T., Peterlin P., Garnier A., Imbert B.-M., Drumel T., Mahé B., Dubruille V., Blin N., et al. Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant. Br. J. Haematol. 2021 doi: 10.1111/bjh.17911. - DOI - PMC - PubMed

Publication types

Supplementary concepts